Dyne Therapeutics Inc’s recently made public that its CEO & President Cox John acquired Company’s shares for reported $0.91 million on Jul 14 ’25. In the deal valued at $9.11 per share,100,000 shares were bought. As a result of this transaction, Cox John now holds 242,179 shares worth roughly $3.27 million.
Then, Scalzo Richard William bought 1,330 shares, generating $19,619 in total proceeds.
Before that, Beskrovnaya Oxana bought 2,132 shares. Dyne Therapeutics Inc shares valued at $31,449 were divested by the Officer at a price of $14.75 per share.
Raymond James upgraded its Dyne Therapeutics Inc [DYN] rating to a Strong buy from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in late June with a ‘”a Mkt perform”‘ rating.
Price Performance Review of DYN
On Tuesday, Dyne Therapeutics Inc [NASDAQ:DYN] saw its stock jump 0.07% to $13.5. Over the last five days, the stock has gained 3.85%. Dyne Therapeutics Inc shares have fallen nearly -70.01% since the year began. Nevertheless, the stocks have fallen -42.70% over the past one year. While a 52-week high of $46.26 was reached on 01/02/25, a 52-week low of $6.36 was recorded on 04/09/25.
Levels Of Support And Resistance For DYN Stock
The 24-hour chart illustrates a support level at 13.17, which if violated will result in even more drops to 12.85. On the upside, there is a resistance level at 13.79. A further resistance level may holdings at 14.09.
How much short interest is there in Dyne Therapeutics Inc?
A steep rise in short interest was recorded in Dyne Therapeutics Inc stocks on 2025-08-15, growing by 1.41 million shares to a total of 17.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 15.73 million shares. There was a rise of 8.23%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 29, 2025 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating along with a $46 price target.
